R. Willemze

Medicine · Health Sciences

40h-index5.9kcitations226works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(69), Hematopoietic Stem Cell Transplantation(66), Acute Lymphoblastic Leukemia research(42), Chronic Lymphocytic Leukemia Research(42), Chronic Myeloid Leukemia Treatments(34)

Publications226 total

Improving the inter- and intra-rater reliability of the body surface area assessment in mycosis fungoides
European Journal of Cancer·2025
A-278 Assessing Inter-Rater Reliability in Mycosis Fungoides: Impact of Clinician Experience on Skin Involvement Assessments
European Journal of Cancer·2024
A-207 Towards guidelines for clinical management of cutaneous lymphoproliferative disorders: an 2024 update
European Journal of Cancer·2024
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials
Cancers·2020· 11 citedOpen Access
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase <scp>III</scp> study
American Journal of Hematology·2020· 17 citedOpen Access
Treatment of rare patients with a primary cutaneous CD30+ lymphoproliferation developing extracutaneous disease: a retrospective study of 43 patients
European Journal of Cancer·2019
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
Haematologica·2018· 13 citedOpen Access
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials
Annals of Hematology·2018· 4 citedOpen Access
PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE, EXPRESS STEREOTYPED B-CELL RECEPTORS WITH UNIQUE NONSYNONYMOUSLY MUTATED CONSTANT REGIONS
Data Archiving and Networked Services (DANS)·2017Open Access
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study
Blood·2016· 2 cited
Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials
Blood·2016
Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial
Haematologica·2016· 5 citedOpen Access
Cutaneous Large Cell Lymphomas of T Cell Origin: Diagnosis, Classification and Prognostic Parameters
Current problems in dermatology·2015· 4 cited
Lymphadenosis benigna cutis versus Primary Cutaneous B-Cell Lymphomas of Follicular Center Cell Origin
Current problems in dermatology·2015· 7 cited
Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial
Blood·2014· 1 cited
Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups
Blood·2014· 11 cited
Clofarabine in combination with a standard remission induction regimen in patients 18-60 years old previously untreated intermediate an bad risk actue myelogenous leukemia (AML) or high risk myelodysplasia (MDS): combined phase I/II results of the EORTC/Gimema AML-14A trial
Open Repository and Bibliography (University of Liège)·2014Open Access
誘導治療での高投与量シタラビンは46歳より若い急性骨髄性白血病成人患者の転帰を改善する: EORTC-GIMEMA AML-12試験
Journal of Clinical Oncology·2014
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
Journal of Clinical Oncology·2013· 165 citedOpen Access
Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials
Blood·2013· 4 cited
page 1 of 12Next →

Frequent Co-authors

Stefan Suciu(7), Willem E. Fibbe(6), R Zittoun(6), Petra Muus(5), Franco Mandelli(5), Bob Löwenberg(5), JH Falkenburg(5), J.H. Frederik Falkenburg(4), Andrea Bacigalupo(4), G. Solbu(4), M. Peetermans(4), Aloïs Gratwohl(4), J. E. Landegent(4), Sicco A. Scherjon(3), Boris Labar(3), Sergio Amadori(3), Dominik Selleslag(3), Erik W.A. Marijt(3), A Hagemeijer(3), U. Jehn(3)